Based on the key indicators related to Windtree Therapeutics' liquidity, profitability, solvency, and operating efficiency, Windtree Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Windtree Therapeutics' Other Liabilities is comparatively stable compared to the past year. Net Receivables is likely to gain to about 94.2 K in 2024, whereas Total Stockholder Equity is likely to drop slightly above 3.2 M in 2024. Key indicators impacting Windtree Therapeutics' financial strength include:
Investors should never underestimate Windtree Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Windtree Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Windtree Therapeutics.
Net Income
(21.31 Million)
Windtree
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Operating Cycle
Cash Conversion Cycle
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Other Non Cash Items
Change To Inventory
Change To Liabilities
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Stock Based Compensation
Net Borrowings
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Change To Account Receivables
Change To Operating Activities
Investments
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Property Plant And Equipment Net
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Total Equity
Other Current Assets
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Common Stock
Non Currrent Assets Other
Inventory
Other Liab
Current Deferred Revenue
Other Assets
Long Term Debt
Treasury Stock
Property Plant Equipment
Net Receivables
Net Tangible Assets
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Short Long Term Debt
Non Current Liabilities Other
Deferred Long Term Liab
Net Invested Capital
Net Working Capital
Capital Stock
Intangible Assets
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Research Development
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Windtree Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Windtree Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Windtree Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Windtree Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Windtree Therapeutics. Check Windtree Therapeutics' Beneish M Score to see the likelihood of Windtree Therapeutics' management manipulating its earnings.
Windtree Therapeutics Stock Summary
Windtree Therapeutics competes with Neurobo Pharmaceuticals, Palisade Bio, Lixte Biotechnology, and Avenue Therapeutics. Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Windtree Therapeutics, Inc. is a subsidiary of Lees Pharmaceutical Holdings Limited. Windtree Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Windtree Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Windtree Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Windtree Therapeutics's current stock value. Our valuation model uses many indicators to compare Windtree Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Windtree Therapeutics competition to find correlations between indicators driving Windtree Therapeutics's intrinsic value. More Info.
Windtree Therapeutics is rated second in return on equity category among its peers. It is rated first in return on asset category among its peers . At this time, Windtree Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Windtree Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Windtree Therapeutics Systematic Risk
Windtree Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Windtree Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on Windtree Therapeutics correlated with the market. If Beta is less than 0 Windtree Therapeutics generally moves in the opposite direction as compared to the market. If Windtree Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Windtree Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Windtree Therapeutics is generally in the same direction as the market. If Beta > 1 Windtree Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Windtree Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Windtree Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Windtree Therapeutics growth as a starting point in their analysis.
Windtree Therapeutics November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Windtree Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Windtree Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Windtree Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Windtree Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Windtree Therapeutics's daily price indicators and compare them against related drivers.
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.